How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

12,122 results for

Rheumatoid Arthritis Management

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Rheumatoid arthritis in adults: management

Rheumatoid arthritis in adults: management Rheumatoid arthritis in adults: Rheumatoid arthritis in adults: management management NICE guideline Published: 11 July 2018 nice.org.uk/guidance/ng100 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available (...) be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Rheumatoid arthritis in adults: management (NG100) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 31Contents Contents Overview 5 Who is it for? 5

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

2. Triple Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for the Management of Rheumatoid Arthritis

Triple Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for the Management of Rheumatoid Arthritis Triple Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for the Management of Rheumatoid Arthritis | CADTH.ca Find the information you need Triple Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for the Management of Rheumatoid Arthritis Triple Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for the Management of Rheumatoid Arthritis Last (...) updated: March 26, 2019 Project Number: RC1087-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the cost-effectiveness of triple conventional synthetic disease-modifying anti-rheumatic drugs compared with other pharmacologic options for the management of rheumatoid arthritis? Key Message Two relevant publications comprising cost-effectiveness analyses were identified; one involved patients with rheumatoid arthritis (RA) that could

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Leflunomide for the Management of Rheumatoid Arthritis: Comparative Clinical Effectiveness

Leflunomide for the Management of Rheumatoid Arthritis: Comparative Clinical Effectiveness Leflunomide for the Management of Rheumatoid Arthritis: Comparative Clinical Effectiveness | CADTH.ca Find the information you need Leflunomide for the Management of Rheumatoid Arthritis: Comparative Clinical Effectiveness Leflunomide for the Management of Rheumatoid Arthritis: Comparative Clinical Effectiveness Last updated: January 15, 2019 Project Number: RA0999-000 Product Line: Research Type: Drug (...) Report Type: Reference List Result type: Report Question What is the clinical effectiveness of leflunomide compared with other disease modifying antirheumatic drugs for the management of rheumatoid arthritis? Key Message One randomized controlled trial was identified regarding the clinical effectiveness of leflunomide for rheumatoid arthritis management. Files Rapid Response Reference List Published : January 15, 2019 Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Adalimumab (Halimatoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis

Adalimumab (Halimatoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 31 May 2018 (...) of the Psoriasis Area and Severity Index (PASI) score PBMC Peripheral blood mononuclear cells PC Process characterisation PD Pharmacodynamics PETG Polyethylene tetraphthalate copolymer PFS Pre-filled syringe Ph. Eur. European Pharmacopoeia PK Pharmacokinetics PP Process parameters PPS Per-protocol analysis set PPso Plaque Psoriasis PsA Psoriatic Arthritis PsO; Ps Psoriasis p.v. Paravenous PV Process validation R2 adj Adjusted correlation coefficient RA Rheumatoid Arthritis RGA Reporter Gene Assay s.c

2018 European Medicines Agency - EPARs

5. Adalimumab (Hyrimoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Papulosquamous Skin Diseases, Hidradenitis Suppurativa, Ankylosing Spondylitis, Uveitis

Adalimumab (Hyrimoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Papulosquamous Skin Diseases, Hidradenitis Suppurativa, Ankylosing Spondylitis, Uveitis 1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how (...) human monoclonal antibody produced in Chinese Hamster Ovary cells. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Clear to slightly opalescent, colourless to slightly yellowish solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Rheumatoid arthritis Hyrimoz in combination with methotrexate, is indicated for: • the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease

2018 European Medicines Agency - EPARs

7. Rituximab Maintenance Therapy for the Treatment and Management of Rheumatoid Arthritis: A Review of Clinical Effectiveness

Rituximab Maintenance Therapy for the Treatment and Management of Rheumatoid Arthritis: A Review of Clinical Effectiveness Rituximab Maintenance Therapy for the Treatment and Management of Rheumatoid Arthritis: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Rituximab Maintenance Therapy for the Treatment and Management of Rheumatoid Arthritis: A Review of Clinical Effectiveness Rituximab Maintenance Therapy for the Treatment and Management of Rheumatoid Arthritis (...) : A Review of Clinical Effectiveness Last updated: July 4, 2018 Project Number: RC0997-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of rituximab maintenance therapy for the treatment and management of rheumatoid arthritis? Key Message Five non-randomized studies were included in this review, of which three were single-arm studies and two were comparative cohorts. The studies were of poor quality overall

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Drugs for the Management of Rheumatoid Arthritis

Drugs for the Management of Rheumatoid Arthritis Drugs for the Management of Rheumatoid Arthritis | CADTH.ca Find the information you need Drugs for the Management of Rheumatoid Arthritis Drugs for the Management of Rheumatoid Arthritis Published on: April 25, 2018 Project Number: HT0010-000 Product Line: Result type: Report Key Messages For rheumatoid arthritis patients with moderate to severe disease in whom treatment with methotrexate has failed or who are intolerant to methotrexate (...) PUBLISHED : April 2018 Health Technology Assessment Clinical Evaluation PUBLISHED : March 2018 Health Technology Assessment Clinical Evaluation - Appendices PUBLISHED : March 2018 Drugs for the management of rheumatoid arthritis: clinical evaluation – Project Protocol Health Technology Assessment Project Protocol PUBLISHED : June 2016 Health Technology Assessment PUBLISHED : May 2017 Health Technology Assessment PUBLISHED : September 2016 Health Technology Assessment PUBLISHED : September 2016 Related

2018 CADTH - Health Technology Assessment

9. The association of obesity with disease activity, functional ability and quality of life in early rheumatoid arthritis: data from the Early Rheumatoid Arthritis Study/Early Rheumatoid Arthritis Network UK prospective cohorts

The association of obesity with disease activity, functional ability and quality of life in early rheumatoid arthritis: data from the Early Rheumatoid Arthritis Study/Early Rheumatoid Arthritis Network UK prospective cohorts To examine associations between BMI and disease activity, functional ability and quality of life in RA.Data from two consecutive, similarly designed UK multicentre RA inception cohorts were used: the Early RA Study (ERAS) and the Early RA Network (ERAN). Recruitment figures (...) was associated with higher DAS28 scores at year 2, but not at year 5, and also associated with significantly higher HAQ and SF-36 PCS scores at years 2 and 5.Obesity prevalence is rising in early RA and associates with worse disease activity, function and health-related quality of life, with a significant negative impact on achieving a low DAS28. The data argue strongly for obesity management to become central to treatment strategies in RA.

2018 EvidenceUpdates

10. Infliximab (Zessly) - Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Psoriasis, Ankylosing Spondylitis

Infliximab (Zessly) - Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Psoriasis, Ankylosing Spondylitis 22 March 2018 EMA/223369/2018 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Zessly International non-proprietary name: infliximab Procedure No. EMEA/H/C/004647/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU (...) Institute ND Not done NS No sample NSAID Nonsteroidal anti-inflammatory drug OBS Observed data PAAP Patient’s Assessment of Arthritis Pain PD Pharmacodynamic(s) PE Physical examination PGA Patient’s Global Assessment of Arthritis PGAA Physician’s Global Assessment of Arthritis PIPD Potentially important protocol deviation PMDA Pharmaceuticals and Medical Devices Agency PK Pharmacokinetic(s) PP Per-Protocol PT Preferred term QC Quality control RA Rheumatoid arthritis RNA Ribonucleic acid SAE Serious

2018 European Medicines Agency - EPARs

11. Intensive management for moderate rheumatoid arthritis: a qualitative study of patients' and practitioners' views. (PubMed)

Intensive management for moderate rheumatoid arthritis: a qualitative study of patients' and practitioners' views. The TITRATE trial seeks to test whether intensive management is valuable in achieving disease remission in moderately active rheumatoid arthritis. Intensive management is a complex intervention consisting of: 1) 12 x monthly appointments, 2) tailored 'treatment support' based on motivational interviewing techniques, 3) optimised medication (including the opportunity for biologics (...) ), 4) provision of a Patient Handbook, and 5) shared treatment planning. This study aims to understand: a) patients' and practitioners' views on the feasibility and acceptability of intensive management, and b) patients' and practitioners' experience of receiving/providing intensive management.A qualitative study, nested within a randomised controlled trial. Participants were patients (n = 15) in the intensive management arm of the trial and rheumatology practitioners (n = 16) providing

2019 Publication 4890932 Controlled trial quality: uncertain

12. Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis

option for severe rheumatoid arthritis that does not respond to conventional therapy. Therapeutic monitoring of TNF-alpha inhibitors could help to optimise their use, improving management of the condition and outcomes that are important for people with rheumatoid arthritis. These include how long their disease is in remission, the rate of flares and relapse, and health-related quality of life. The clinical-effectiveness evidence for ELISA tests for therapeutic monitoring of TNF-alpha inhibitors (...) person to person, but often results in substantial morbidity, impaired physical activity, poor quality of life, and reduced life expectancy. It is marked by relapses (when the disease flares up) and remission (when there are few or no signs or symptoms). Rheumatoid arthritis is currently incurable, and people will remain on treatment for the rest of their lives. The care pathways 2.7 Initial diagnosis and management of rheumatoid arthritis, including monitoring of treatment response, are covered

2019 National Institute for Health and Clinical Excellence - Diagnostics Guidance

13. Group cognitive behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations

Group cognitive behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations Group cognitive behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from (...) the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} CBT plus usual care, delivered by clinical rheumatology teams, reduced fatigue impact in rheumatoid arthritis at 26 weeks beyond usual care alone, but with uncertain cost-effectiveness. {{author}} {{($index , , , , , , , , , , , , , & . Sarah Hewlett 1, * , Celia Almeida 1 , Nicholas Ambler 2 , Peter S Blair 3 , Ernest Choy 4

2019 NIHR HTA programme

14. Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity. (PubMed)

Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity. Even with optimal disease-modifying treatment and good control of disease activity, persistent pain due to structural damage is common in people with inflammatory arthritis and therefore additional treatment for pain might be required. Because comorbidity is highly prevalent in people with inflammatory arthritis (...) ). The study population comprised adults (>18 years) with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or other spondyloarthritis who had gastrointestinal and/or hepatic comorbid conditions. Outcomes of interest were pain, adverse effects, function and quality of life. Studies that included a mixed population of inflammatory arthritis and other conditions were included only if results for inflammatory arthritis were reported separately.Two review authors independently selected trials

2012 Cochrane

15. Upadacitinib (Rinvoq) - rheumatoid arthritis

Upadacitinib (Rinvoq) - rheumatoid arthritis CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 211675Orig1s000 CLINICAL REVIEW(S) Clinical Review Keith M Hull, MD, PhD NDA 211675 RINVOQ (upadacitinib) CLINICAL REVIEW Application Type NDA Application Number(s) 211675 Priority or Standard Priority Submit Date(s) 18 Dec 2018 Received Date(s) 18 Dec 2018 PDUFA Goal Date 18 Aug 2019 Division/Office Division of Pulmonary, Allergy and Rheumatology Products Reviewer Name(s) Keith M Hull, MD (...) , PhD Review Completion Date 17 May 2019 Established/Proper Name Upadacitinib (Proposed) Trade Name RINVOQ Applicant AbbVie Inc Dosage Form(s) 15 mg extended release tablets Applicant Proposed Dosing Regimen(s) 15 mg orally administered QD Applicant Proposed Indication(s)/Population(s) Recommendation on Regulatory Action Approval Recommended Indication(s)/Population(s) (if applicable) Treatment of adults with moderately to severely active rheumatoid arthritis who had an inadequate response

2019 FDA - Drug Approval Package

16. Randomised controlled trial: Combining nurse-led care with patient self-assessment could enhance tight control of rheumatoid arthritis and management of comorbidities

Randomised controlled trial: Combining nurse-led care with patient self-assessment could enhance tight control of rheumatoid arthritis and management of comorbidities Combining nurse-led care with patient self-assessment could enhance tight control of rheumatoid arthritis and management of comorbidities | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) of rheumatoid arthritis and management of comorbidities Article Text Primary health care Randomised controlled trial Combining nurse-led care with patient self-assessment could enhance tight control of rheumatoid arthritis and management of comorbidities Mwidimi Ndosi Correspondence to : Dr Mwidimi Ndosi, University of Leeds, School of Healthcare, Baines Wing, Leeds LS2 9JT, UK; m.e.ndosi{at}leeds.ac.uk Statistics from Altmetric.com Commentary on : Dougados M , Soubrier M , Perrodeau E , et al . Impact

Full Text available with Trip Pro

2016 Evidence-Based Nursing

17. Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). (PubMed)

Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Despite optimal therapy with disease-modifying antirheumatic drugs, many people with inflammatory arthritis (IA) continue to have persistent pain that may require additional therapy.To assess the benefits and safety of combination pain therapy for people with IA (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis

2011 Cochrane

18. Diagnosis and Management of Rheumatoid Arthritis: A Review. (PubMed)

Diagnosis and Management of Rheumatoid Arthritis: A Review. Rheumatoid arthritis (RA) occurs in about 5 per 1000 people and can lead to severe joint damage and disability. Significant progress has been made over the past 2 decades regarding understanding of disease pathophysiology, optimal outcome measures, and effective treatment strategies, including the recognition of the importance of diagnosing and treating RA early.Early diagnosis and treatment of RA can avert or substantially slow

2018 JAMA

19. Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry (PubMed)

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry Current recommendations for the management of rheumatoid arthritis (RA) focus on a treat-to-target approach with the objective of maximizing long-term health-related quality-of-life in patients with RA. Published studies from randomized clinical trials have reported limited data regarding the long-term efficacy and safety of adalimumab in patients

Full Text available with Trip Pro

2017 Rheumatology and therapy

20. Evaluation of Usability and Acceptance of a New Autoinjector Intended for Methotrexate Subcutaneous Self-Administration in the Management of Rheumatoid Arthritis (PubMed)

Evaluation of Usability and Acceptance of a New Autoinjector Intended for Methotrexate Subcutaneous Self-Administration in the Management of Rheumatoid Arthritis Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease, for which the introduction of injectable treatments has had a major impact on quality of life directly related to the disease. The purpose of this descriptive study was to evaluate the usability of a new autoinjector, intended for methotrexate self-administration

Full Text available with Trip Pro

2017 Rheumatology and therapy

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>